卵巣疾患、卵巣病

WordNet

an impairment of health or a condition of abnormal functioning
caused by or altered by or manifesting disease or pathology; "diseased tonsils"; "a morbid growth"; "pathologic tissue"; "pathological bodily processes" (同)morbid, pathologic, pathological
of or involving the ovaries; "ovarian cancer"

PrepTutorEJDIC

(体の)『病気』,疾患 / (精神・道徳などの)病気,病弊
女性の話術芸人 =diseur
病気にかかった / 病的な,不健全な(morbid)
卵巣の / 子房(しぼう)の

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/10/15 11:49:06」(JST)

wiki en

[Wiki en表示]

Ovarian diseases can be classified as endocrine disorders or as a disorders of the reproductive system.

If the egg fails to release from the follicle in the ovary an ovarian cyst may form. Small ovarian cysts are common in healthy women. Some women have more follicles than usual (polycystic ovary syndrome), which inhibits the follicles to grow normally and this will cause cycle irregularities.

Other conditions include:

Ovarian cancer
Luteoma
Hypogonadism
Hyperthecosis

This article about a disease, disorder, or medical condition is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 子宮摘出時の選択的卵巣摘出術または卵巣保全 elective oophorectomy or ovarian conservation at the time of hysterectomy
2. 妊娠中における卵巣癌の化学療法 chemotherapy of ovarian cancer in pregnancy
3. 骨盤内炎症性疾患：臨床症状および診断 pelvic inflammatory disease clinical manifestations and diagnosis
4. 先天性心疾患女性における妊娠：一般原則 pregnancy in women with congenital heart disease general principles
5. 上皮性卵巣癌、卵管癌、または腹膜癌の再発に対する薬物療法：プラチナ製剤抵抗性癌 medical treatment for relapsed epithelial ovarian fallopian tubal or peritoneal cancer platinum resistant disease

English Journal

Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.

Zhang M1,2,3, Zhang M1,3, Wang J1, Cai Q1,3, Zhao R1, Yu Y1, Tai H1, Zhang X1,3, Xu C1,3.
Drug delivery.Drug Deliv.2018 Nov;25(1):995-1003. doi: 10.1080/10717544.2018.1461956.
PMID 29667478

Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.

Zhang MX1, Hong SS1, Cai QQ1,2,3, Zhang M1, Chen J4, Zhang XY1,2,3, Xu CJ1,2,3.
Drug delivery.Drug Deliv.2018 Nov;25(1):797-806. doi: 10.1080/10717544.2018.1451934.
PMID 29542355

Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer.

Hong SS1, Zhang MX1, Zhang M1, Yu Y1, Chen J2, Zhang XY1,3,4, Xu CJ1,3,4.
Drug delivery.Drug Deliv.2018 Nov;25(1):576-584. doi: 10.1080/10717544.2018.1440667. Epub 2018 Feb 20.
PMID 29461120

Japanese Journal

難治性卵巣癌の浸潤・転移に関わる分子をターゲットとした新規治療法の開発(シンポジウム2(腫瘍) 難治性卵巣癌の克服を目指して,第66回日本産科婦人科学会学術講演会講演要旨)

寺井義人
日本産科婦人科學會雜誌 66(11), 2771-2776, 2014-11-01
… Epithelial ovarian carcinoma is a major cause of death among the gynecological malignancies. … This is primarily due to the lack of methods for an early detection of the disease leading to rapid, aggressive peritoneal dissemination of cells from the primary tumor, which results in an adverse prognosis for the most patients. … Therefore, we examined the molecular mechanisms involved in the regulatory association between EMT and CD24 in ovarian cancer. …
NAID 110009872636

卵巣癌幹細胞および癌幹細胞ニッチとして機能する骨盤腹膜を標的とした新たな治療戦略(シンポジウム2(腫瘍) 難治性卵巣癌の克服を目指して,第66回日本産科婦人科学会学術講演会講演要旨)

本原剛志
日本産科婦人科學會雜誌 66(11), 2761-2770, 2014-11-01
… Ovarian cancer is the leading cause of gynecological cancer-related death. … The clinical outcome of patients with ovarian cancer is poor because the majority of patients are diagnosed in advanced stages with multiple disseminated tumors in the pelvic peritoneum. …
NAID 110009872635

卵巣明細胞腺癌に対する線維芽細胞増殖因子受容体(FGFR)2シグナル伝達経路を標的とした新規治療戦略(シンポジウム2(腫瘍) 難治性卵巣癌の克服を目指して,第66回日本産科婦人科学会学術講演会講演要旨)

板持広明
日本産科婦人科學會雜誌 66(11), 2751-2760, 2014-11-01
… The aim of the present study was to identify biomarkers that are predictive of the outcome of patients with CCC, and to seek a novel therapeutic target for this disease. … Eleven CCC cell lines and five ovarian serous adenocarcinoma (SAC) cell lines were used. … The expression of FGFR2 was found in 96% (108/112) of CCC by immunohistochemical analysis and was not associated with protein expression of the PI3K/Akt/mTOR signaling pathway and the stage of the disease. …
NAID 110009872634